Naratriptan

Table   Graphic  
  individual studies
OutcomeTE95% CIn casesn exposedkPub. bias All congenital malformations (majors, minors, majors and minors, or unspecified) Källén (control unexposed, disease free), 2011 Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018 30.50[0.14; 1.77]56,846161not evaluable Major congenital malformations Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018 20.31[0.06; 1.63]86139not evaluable Early intrauterine death (< 22 weeks) Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018 21.02[0.71; 1.46]701242not evaluable Elective termination of pregnancy Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018 20.91[0.44; 1.87]160247not evaluable Late intrauterine deaths (> 22 weeks) Ephross (Naratriptan versus Sumatriptan), 2014 Yusuf (Control exposed to Sumatriptan), 2018 20.79[0.10; 5.99]19247not evaluable0.010.01.0